These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

347 related items for PubMed ID: 22441743

  • 1. Efficacy and safety of twice-daily aclidinium bromide in COPD patients: the ATTAIN study.
    Jones PW, Singh D, Bateman ED, Agusti A, Lamarca R, de Miquel G, Segarra R, Caracta C, Garcia Gil E.
    Eur Respir J; 2012 Oct; 40(4):830-6. PubMed ID: 22441743
    [Abstract] [Full Text] [Related]

  • 2. Efficacy and safety of a 12-week treatment with twice-daily aclidinium bromide in COPD patients (ACCORD COPD I).
    Kerwin EM, D'Urzo AD, Gelb AF, Lakkis H, Garcia Gil E, Caracta CF, ACCORD I study investigators.
    COPD; 2012 Apr; 9(2):90-101. PubMed ID: 22320148
    [Abstract] [Full Text] [Related]

  • 3. Efficacy of aclidinium bromide 400 μg twice daily compared with placebo and tiotropium in patients with moderate to severe COPD.
    Fuhr R, Magnussen H, Sarem K, Llovera AR, Kirsten AM, Falqués M, Caracta CF, Garcia Gil E.
    Chest; 2012 Mar; 141(3):745-752. PubMed ID: 21903737
    [Abstract] [Full Text] [Related]

  • 4. Nebulized arformoterol in patients with COPD: a 12-week, multicenter, randomized, double-blind, double-dummy, placebo- and active-controlled trial.
    Baumgartner RA, Hanania NA, Calhoun WJ, Sahn SA, Sciarappa K, Hanrahan JP.
    Clin Ther; 2007 Feb; 29(2):261-78. PubMed ID: 17472819
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. The potential for aclidinium bromide, a new anticholinergic, in the management of chronic obstructive pulmonary disease.
    Maltais F, Milot J.
    Ther Adv Respir Dis; 2012 Dec; 6(6):345-61. PubMed ID: 23075544
    [Abstract] [Full Text] [Related]

  • 8. ACCORD COPD II: a randomized clinical trial to evaluate the 12-week efficacy and safety of twice-daily aclidinium bromide in chronic obstructive pulmonary disease patients.
    Rennard SI, Scanlon PD, Ferguson GT, Rekeda L, Maurer BT, Garcia Gil E, Caracta CF.
    Clin Drug Investig; 2013 Dec; 33(12):893-904. PubMed ID: 24085591
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Long-term safety and efficacy of twice-daily aclidinium bromide in patients with COPD.
    Gelb AF, Tashkin DP, Make BJ, Zhong X, Garcia Gil E, Caracta C, LAS-MD-35 study investigators.
    Respir Med; 2013 Dec; 107(12):1957-65. PubMed ID: 23916502
    [Abstract] [Full Text] [Related]

  • 11. Reduction in clinically important deterioration in chronic obstructive pulmonary disease with aclidinium/formoterol.
    Singh D, D'Urzo AD, Chuecos F, Muñoz A, Garcia Gil E.
    Respir Res; 2017 May 30; 18(1):106. PubMed ID: 28558833
    [Abstract] [Full Text] [Related]

  • 12. Onset of effect of aclidinium, a novel, long-acting muscarinic antagonist, in patients with COPD.
    Vestbo J, Vogelmeier C, Creemers J, Falques M, Ribera A, Gil EG.
    COPD; 2010 Oct 30; 7(5):331-6. PubMed ID: 20854047
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Once-daily bronchodilators for chronic obstructive pulmonary disease: indacaterol versus tiotropium.
    Donohue JF, Fogarty C, Lötvall J, Mahler DA, Worth H, Yorgancioglu A, Iqbal A, Swales J, Owen R, Higgins M, Kramer B, INHANCE Study Investigators.
    Am J Respir Crit Care Med; 2010 Jul 15; 182(2):155-62. PubMed ID: 20463178
    [Abstract] [Full Text] [Related]

  • 15. Aclidinium bromide: an alternative long-acting inhaled anticholinergic in the management of chronic obstructive pulmonary disease.
    Woods JA, Nealy KL, Barrons RW.
    Ann Pharmacother; 2013 Jul 15; 47(7-8):1017-28. PubMed ID: 23737515
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Improvement in 24-hour bronchodilation and symptom control with aclidinium bromide versus tiotropium and placebo in symptomatic patients with COPD: post hoc analysis of a Phase IIIb study.
    Beier J, Mroz R, Kirsten AM, Chuecos F, Gil EG.
    Int J Chron Obstruct Pulmon Dis; 2017 Jul 15; 12():1731-1740. PubMed ID: 28652725
    [Abstract] [Full Text] [Related]

  • 20. Bronchodilatory effects of aclidinium bromide, a long-acting muscarinic antagonist, in COPD patients.
    Joos GF, Schelfhout VJ, Pauwels RA, Kanniess F, Magnussen H, Lamarca R, Jansat JM, Garcia Gil E.
    Respir Med; 2010 Jun 15; 104(6):865-72. PubMed ID: 20044242
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.